123 related articles for article (PubMed ID: 27836688)
1. Pathologic significance of SET/I2PP2A-mediated PP2A and non-PP2A pathways in polycystic ovary syndrome (PCOS).
Jiang SW; Xu S; Chen H; Liu X; Tang Z; Cui Y; Liu J
Clin Chim Acta; 2017 Jan; 464():155-159. PubMed ID: 27836688
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic Role of SET/I2PP2A for Gynecologic Cancers.
Jiang SW; Xu S; Chen H; Liu J; Duan P
Curr Drug Targets; 2017; 18(10):1152-1157. PubMed ID: 28356029
[TBL] [Abstract][Full Text] [Related]
3. Zinc Finger and X-Linked Factor (ZFX) Binds to Human SET Transcript 2 Promoter and Transactivates SET Expression.
Xu S; Duan P; Li J; Senkowski T; Guo F; Chen H; Romero A; Cui Y; Liu J; Jiang SW
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27775603
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
[TBL] [Abstract][Full Text] [Related]
5. The interaction of SET and protein phosphatase 2A as target for cancer therapy.
Dacol EC; Wang S; Chen Y; Lepique AP
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188578. PubMed ID: 34116173
[TBL] [Abstract][Full Text] [Related]
6. SET improved oocyte maturation by serine/threonine protein phosphatase 2A and inhibited oocyte apoptosis in mouse oocytes.
Gao L; Wang S; Xu J; Lu D; Cui Y
Reprod Biol; 2022 Sep; 22(3):100668. PubMed ID: 35728284
[TBL] [Abstract][Full Text] [Related]
7. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer.
Farrell AS; Allen-Petersen B; Daniel CJ; Wang X; Wang Z; Rodriguez S; Impey S; Oddo J; Vitek MP; Lopez C; Christensen DJ; Sheppard B; Sears RC
Mol Cancer Res; 2014 Jun; 12(6):924-39. PubMed ID: 24667985
[TBL] [Abstract][Full Text] [Related]
8. Isoliensinine induces dephosphorylation of NF-kB p65 subunit at Ser536 via a PP2A-dependent mechanism in hepatocellular carcinoma cells: roles of impairing PP2A/I2PP2A interaction.
Shu G; Zhang L; Jiang S; Cheng Z; Wang G; Huang X; Yang X
Oncotarget; 2016 Jun; 7(26):40285-40296. PubMed ID: 27244888
[TBL] [Abstract][Full Text] [Related]
9. [Genetic aspects of polycystic ovary syndrome].
Jakubowski L
Endokrynol Pol; 2005; 56(3):285-93. PubMed ID: 16350721
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.
Hu X; Garcia C; Fazli L; Gleave M; Vitek MP; Jansen M; Christensen D; Mulholland DJ
Sci Rep; 2015 Nov; 5():15182. PubMed ID: 26563471
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
Gambineri A; Patton L; De Iasio R; Palladoro F; Pagotto U; Pasquali R
J Clin Endocrinol Metab; 2007 Jun; 92(6):2066-73. PubMed ID: 17356050
[TBL] [Abstract][Full Text] [Related]
12. Increased protein expression of LHCG receptor and 17α-hydroxylase/17-20-lyase in human polycystic ovaries.
Comim FV; Teerds K; Hardy K; Franks S
Hum Reprod; 2013 Nov; 28(11):3086-92. PubMed ID: 24014605
[TBL] [Abstract][Full Text] [Related]
13. A genetic risk score is associated with polycystic ovary syndrome-related traits.
Lee H; Oh JY; Sung YA; Chung HW
Hum Reprod; 2016 Jan; 31(1):209-15. PubMed ID: 26573528
[TBL] [Abstract][Full Text] [Related]
14. PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer.
González-Alonso P; Cristóbal I; Manso R; Madoz-Gúrpide J; García-Foncillas J; Rojo F
Tumour Biol; 2015 Aug; 36(8):5753-5. PubMed ID: 26234767
[TBL] [Abstract][Full Text] [Related]
15. Ceramide in the prostate.
Dent P
Cancer Biol Ther; 2013 Oct; 14(10):881-2. PubMed ID: 24025252
[TBL] [Abstract][Full Text] [Related]
16. Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models.
Caldwell AS; Middleton LJ; Jimenez M; Desai R; McMahon AC; Allan CM; Handelsman DJ; Walters KA
Endocrinology; 2014 Aug; 155(8):3146-59. PubMed ID: 24877633
[TBL] [Abstract][Full Text] [Related]
17. A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia.
Arriazu E; Vicente C; Pippa R; Peris I; Martínez-Balsalobre E; García-Ramírez P; Marcotegui N; Igea A; Alignani D; Rifón J; Mateos MC; Cayuela ML; Nebreda AR; Odero MD
Blood Cancer J; 2020 Jan; 10(1):3. PubMed ID: 31913266
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II type 2 receptor stimulation improves fatty acid ovarian uptake and hyperandrogenemia in an obese rat model of polycystic ovary syndrome.
Leblanc S; Battista MC; Noll C; Hallberg A; Gallo-Payet N; Carpentier AC; Vine DF; Baillargeon JP
Endocrinology; 2014 Sep; 155(9):3684-93. PubMed ID: 24971613
[TBL] [Abstract][Full Text] [Related]
19. Expression and clinical significance of the HIF-1a/ET-2 signaling pathway during the development and treatment of polycystic ovary syndrome.
Wang F; Zhang Z; Wang Z; Xiao K; Wang Q; Su J; Wang Z
J Mol Histol; 2015 Apr; 46(2):173-81. PubMed ID: 25613530
[TBL] [Abstract][Full Text] [Related]
20. A Dietary Medium-Chain Fatty Acid, Decanoic Acid, Inhibits Recruitment of Nur77 to the HSD3B2 Promoter In Vitro and Reverses Endocrine and Metabolic Abnormalities in a Rat Model of Polycystic Ovary Syndrome.
Lee BH; Indran IR; Tan HM; Li Y; Zhang Z; Li J; Yong EL
Endocrinology; 2016 Jan; 157(1):382-94. PubMed ID: 26465200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
